Genexine, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 0.00035 million compared to KRW 0.23963 million a year ago. Net loss was KRW 18,788.56 million compared to KRW 16,304.21 million a year ago. Basic loss per share from continuing operations was KRW 574.6154 compared to KRW 501.5385 a year ago. Diluted loss per share from continuing operations was KRW 574.6154 compared to KRW 501.5385 a year ago. Basic loss per share was KRW 574.6154 compared to KRW 501.5385 a year ago.
For the nine months, sales was KRW 4.72 million compared to KRW 135.53 million a year ago. Net loss was KRW 17,609.19 million compared to KRW 15,092.94 million a year ago. Basic loss per share from continuing operations was KRW 540 compared to KRW 466.1538 a year ago. Diluted loss per share from continuing operations was KRW 540 compared to KRW 466.1538 a year ago. Basic loss per share was KRW 540 compared to KRW 466.1538 a year ago.